Dataset Information

Bidirectional and persistent immunomodulation of Astragalus polysaccharide as an adjuvant of influenza and recombinant SARS-CoV-2 vaccine.

ABSTRACT: Respiratory viral infections, such as coronavirus disease of 2019 (COVID-19) and influenza, cause significant morbidity and mortality and have become a worldwide public health concern with tremendous economic and societal burdens. Vaccination is a major strategy for preventing infections. However, some new vaccines have an unmet need for impairing responses in certain individuals, especially COVID-19 vaccines, despite ongoing vaccine and adjuvant research. Here, we evaluated the effectiveness of Astragalus polysaccharide (APS), a bioactive polysaccharide extracted from the traditional Chinese herb Astragalus membranaceus as an immune adjuvant to regulate the efficacy of influenza split vaccine (ISV) and recombinant severe acute respiratory syndrome (SARS)-Cov-2 vaccine in mice. Our data indicated that APS as an adjuvant can facilitate the induction of high levels of hemagglutination inhibition (HAI) titer and specific antibody immunoglobulin G (IgG) and confer protection against the lethal challenge of influenza A viruses, including increased survival and amelioration of weight loss in mice immunized with the ISV. RNA sequencing (RNA-seq) analysis revealed that the NF-κB and Fc gamma R-mediated phagocytosis signaling pathways are essential for the immune response of mice immunized with the recombinant SARS-Cov-2 vaccine (RSV). Another important finding was that bidirectional immunomodulation of APS on cellular and humoral immunity was observed, and APS-adjuvant-induced antibodies persisted at a high level for at least 20 weeks. These findings suggest that APS is a potent adjuvant for influenza and COVID-19 vaccines, and has the advantages of bidirectional immunoregulation and persistent immunity.

SUBMITTER: Zhao D

PROVIDER: S-EPMC9932796 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Bidirectional and persistent immunomodulation of Astragalus polysaccharide as an adjuvant of influenza and recombinant SARS-CoV-2 vaccine.

Zhao Danping D Chen Xiuhong X Wang Linyuan L Zhang Jianjun J Zhao Zhongpeng Z Yue Na N Zhu Yingli Y Fei Wenting W Li Xinyu X Tan Lingyun L He Wei W

International journal of biological macromolecules 20230216

Respiratory viral infections, such as coronavirus disease of 2019 (COVID-19) and influenza, cause significant morbidity and mortality and have become a worldwide public health concern with tremendous economic and societal burdens. Vaccination is a major strategy for preventing infections. However, some new vaccines have an unmet need for impairing responses in certain individuals, especially COVID-19 vaccines, despite ongoing vaccine and adjuvant research. Here, we evaluated the effectiveness of ...[more]

PMID: 36801224

Similar Datasets

Project description:Porcine epidemic diarrhea virus (PEDV), the major causative pathogen of porcine epidemic diarrhea, poses a severe threat to the swine industry, particularly affecting neonatal piglets. Maternal milk-derived IgA antibody is crucial for protecting piglets from PEDV infection. Despite the effectiveness of current intramuscularly administered PEDV vaccines in inducing strong systemic immune responses, their ability to generate high levels of maternal milk IgA is limited. This study explores the potential of Astragalus polysaccharide (APS) to enhance PEDV vaccine efficacy, specifically focusing on maternal milk IgA levels. We first evaluated anti-PEDV antibody levels in the blood and colostrum of sows vaccinated with PEDV or subjected to feedback feeding. Our results indicated that while vaccination induced robust serum PEDV-specific IgG and IgA, milk IgA levels were lower compared to the feedback group. To address this limitation, APS was administered orally to sows before PEDV vaccination. APS supplementation significantly increased both serum and milk PEDV-specific IgA levels and enhanced cellular immune responses, as evidenced by elevated cytokine levels. Further analysis demonstrated that APS improved intestinal immune function and homeostasis in piglets. Overall, APS supplementation proved to be an effective immune booster, enhancing PEDV vaccine-induced mucosal immunity and providing a promising strategy for improving maternal immunity and piglet protection against PEDV.ImportanceThis study highlights the limitations of current porcine epidemic diarrhea virus (PEDV) vaccines in inducing sufficient maternal milk IgA, which is crucial for protecting neonatal piglets. By supplementing Astragalus polysaccharide (APS) into the vaccination regimen, we demonstrated a significant enhancement in milk PEDV-specific IgA levels, as well as improved cellular immune responses. APS also bolstered intestinal immune function and homeostasis in piglets. These findings suggest that APS supplementation could serve as an immune booster to enhance maternal immunity, offering a promising approach to better protect piglets against PEDV.

Dataset Information

Bidirectional and persistent immunomodulation of Astragalus polysaccharide as an adjuvant of influenza and recombinant SARS-CoV-2 vaccine.

Publications

Bidirectional and persistent immunomodulation of Astragalus polysaccharide as an adjuvant of influenza and recombinant SARS-CoV-2 vaccine.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets